Sanofi jumpstarts effort to supply 30 'essential' drugs to lower-income countries
05 Jul 2022
A week after Sanofi promised to cut insulin prices, the pharma giant’s nonprofit unit has agreed to make the life-saving drug and 29 others available to 40 lower-income countries.
Together, the medicines will form what Sanofi calls the Impact brand. They cover a range of diseases, from diabetes to cardiovascular disease to cancer, and are considered essential by the World Health Organization, the company said.
The effort falls under Sanofi’s nonprofit unit Sanofi Global Health, which was launched just last year.
“Sanofi Global Health aims to improve the lives of millions of people who now cannot get the help they need. Sanofi’s renewed purpose is to chase the miracles of science to improve people’s lives. And our quest to make life better for all people must include helping to provide better access to care and quality medicines for underserved populations,” CEO Paul Hudson said in a statement.
The type 2 diabetes treatment glibenclamide and chemotherapy oxaliplatin are also on the list, according to Sanofi.
In addition to the medicines, Sanofi is establishing an Impact fund to support startups looking for sustainable healthcare solutions in underserved regions by offering financing and technical assistance. The pharma giant is getting the ball rolling with $25 million, according to a
Reuters
report.
“We know that we cannot do this alone, and so we are building partnerships at global, regional and local levels that will help to improve and establish health systems to reach our goal of a healthier, more resilient world,” Jon Fairest, head of Sanofi Global Health, said in the statement.
Last Wednesday, Sanofi announced that it would cut the monthly price of its insulins for uninsured Americans from $99 down to $35. The move follows the House passage of a monthly cap back in March, which just 12 Republicans supported.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.